Efficacy and Safety of the DPP-IV Inhibitor PF-734200 Added to Metformin in Subjects with Type 2 Diabetes Mellitus

被引：0
|
作者：
Terra, Steven G.
Somayaji, Veena
Teeter, John G.
Dai, Haiqing
Nguyen, Tu T.
Ghazzi, Mahmoud
机构：
来源：
DIABETES | 2009年 / 58卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：A134 / A135
页数：2
相关论文
共 50 条
  • [1] A Dose-Ranging Study of the DPP-IV Inhibitor PF-734200 Added to Metformin in Subjects with Type 2 Diabetes Mellitus
    Terra, Steven G.
    Somayaji, Veena
    Calle, Boberto A.
    Dai, Haiqing
    Nguyen, Tu T.
    Teeter, John G.
    Ghazzi, Mahmoud
    DIABETES, 2009, 58 : A512 - A512
  • [2] A Dose-Ranging Study of the DPP-IV Inhibitor PF-734200 Added to Metformin in Subjects With Type 2 Diabetes
    Terra, S. G.
    Somayaji, V.
    Schwartz, S.
    Lewin, A. J.
    Teeter, J. G.
    Dai, H.
    Nguyen, T. T.
    Calle, R. A.
    EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2011, 119 (07) : 401 - 407
  • [3] The pharmacokinetics of PF-734200, a DPP-IV inhibitor, in subjects with renal insufficiency
    Dai, Haiqing
    Johnson, Susan L.
    Terra, Steven G.
    Marbury, Thomas C.
    Smith, William B.
    Alcorn, Harry
    Boyd, Rebecca A.
    Wang, Rong
    Nguyen, Tu T.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2011, 72 (01) : 85 - 91
  • [4] The Pharmacokinetics of PF-734200, a DPP-IV Inhibitor, in Subjects with Renal Insufficiency
    Dai, Haiqing
    Johnson, Susan L.
    Terra, Steven G.
    Mar-Bury, Thomas C.
    Smith, William B.
    Fuentes, Ernesto
    Alcorn, Harry
    Boyd, Rebecca
    Nguyen, Tu T.
    Ghazzi, Mahmoud
    DIABETES, 2009, 58 : A162 - A162
  • [5] Pharmacokinetics and Pharmacodynamics of PF-734200, a DPP-IV Inhibitor, in Healthy Japanese Subjects
    Dai, Haiqing
    Johnson, Susan L.
    Muto, Chieko
    Banerjee, Subhashis
    Yachi, Yasunori
    Nguyen, Tu T.
    Ghazzi, Mahmoud
    DIABETES, 2009, 58 : A534 - A534
  • [6] Efficacy and safety of the dipeptidyl peptidase-4 inhibitor PF-734200 added to metformin in Type 2 diabetes
    Rosenstock, J.
    Lewin, A. J.
    Norwood, P.
    Somayaji, V.
    Nguyen, T. T.
    Teeter, J. G.
    Johnson, S. L.
    Dai, H.
    Terra, S. G.
    DIABETIC MEDICINE, 2011, 28 (04) : 464 - 469
  • [7] Effects of multiple doses of the DPP-IV inhibitor PF-734200 on the relationship between GLP-1 and glucose in subjects with type 2 diabetes mellitus
    Gustavson, Stephanie M.
    Dai, Haiqing
    Preston, Gregory M.
    Somayaji, Veena
    Hirshberg, Boaz
    Calle, Roberto A.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2011, 91 (02) : E45 - E49
  • [8] Efficacy, Safety, and Dose-Response Relationship of Teneligliptin, a Novel DPP-IV Inhibitor, in Japanese Patients with Type 2 Diabetes Mellitus
    Kadowaki, Takashi
    Marubayashi, Fuyuhiko
    Terata, Ryuuji
    Hayashi, Yoshiharu
    DIABETES, 2010, 59 : A156 - A157
  • [9] Management of Type 2 Diabetes Mellitus by DPP-IV Inhibition - A Review
    Divya, K.
    Vivek, H. K.
    Prasad, Nagendra M. N.
    Priya, B. S.
    Swamy, Nanjunda S.
    INTERNATIONAL JOURNAL OF PHARMACEUTICAL AND PHYTOPHARMACOLOGICAL RESEARCH, 2014, 4 (02): : 138 - 143
  • [10] To investigate the efficacy of dipeptidyl peptidase-IV (DPP-IV) inhibitor therapy in multiethnic Asian patients with type 2 diabetes mellitus
    Andres, Julia
    Yeo, Jia Xuan
    Khoo, Chin Meng
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2016, 120 : S123 - S124
12345